A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease by Sahasrabuddhe, Vikrant et al.
RESEARCH ARTICLE
A Single-Arm, Proof-Of-Concept Trial of
Lopimune (Lopinavir/Ritonavir) as a
Treatment for HPV-Related Pre-Invasive
Cervical Disease
Lynne Hampson1☯, Innocent O. Maranga2,3☯, Millicent S. Masinde3, AnthonyW. Oliver1,
Gavin Batman1, Xiaotong He1, Minaxi Desai4, Parmenas M. Okemwa3, Helen Stringfellow5,
Pierre Martin-Hirsch6, Alex M. Mwaniki3, Peter Gichangi3, Ian N. Hampson1*
1 University of Manchester Viral Oncology Laboratories, Institute of Cancer Sciences, Research Floor 5, St
Mary’s Hospital, Oxford Road, Manchester M13 9WL, United Kingdom, 2 Kenyatta National Hospital,
Department of Reproductive Health, PO Box 20723–00202, Nairobi, Kenya, 3 University of Nairobi, College
of Health Sciences, Departments of Gynaecology and Pathology, PO Box 19676–00202, Nairobi, Kenya,
4 Cytology Laboratories, PO Box 208, Clinical Sciences Building 2, Central Manchester University Hospital
NHS Trust, Oxford Rd, Manchester M13 9WW, United Kingdom, 5 Department of Pathology, Royal Preston
Hospital, Sharoe Green Lane, Fulwood, Preston, PR2 9HT, United Kingdom, 6 Department of Obstetrics &
Gynaecology, Royal Preston Hospital, Sharoe Green Lane, Fulwood, Preston, PR2 9HT, United Kingdom
☯ These authors contributed equally to this work.
* ian.hampson@manchester.ac.uk
Abstract
Background
Cervical cancer is the most common female malignancy in the developing nations and the
third most common cancer in women globally. An effective, inexpensive and self-applied
topical treatment would be an ideal solution for treatment of screen-detected, pre-invasive
cervical disease in low resource settings.
Methods
Between 01/03/2013 and 01/08/2013, women attending Kenyatta National Hospital's Family
Planning and Gynaecology Outpatients clinics were tested for HIV, HPV (Cervista1) and liq-
uid based cervical cytology (LBC -ThinPrep1). HIV negative women diagnosed as high-risk
HPV positive with high grade squamous intraepithelial lesions (HSIL) were examined by
colposcopy and given a 2 week course of 1 capsule of Lopimune (CIPLA) twice daily, to be
self-applied as a vaginal pessary. Colposcopy, HPV testing and LBCwere repeated at 4 and
12 weeks post-start of treatment with a final punch biopsy at 3 months for histology. Primary
outcomemeasures were acceptability of treatment with efficacy as a secondary consideration.
Results
A total of 23 women with HSIL were treated with Lopimune during which time no adverse
reactions were reported. A maximum concentration of 10 ng/ml of lopinavir was detected in
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patient plasma 1 week after starting treatment. HPV was no longer detected in 12/23
(52.2%, 95%CI: 30.6–73.2%). Post-treatment cytology at 12 weeks on women with HSIL,
showed 14/22 (63.6%, 95%CI: 40.6–82.8%) had no dysplasia and 4/22 (18.2%, 95%CI:
9.9–65.1%) were now low grade demonstrating a combined positive response in 81.8% of
women of which 77.8% was confirmed by histology. These data are supported by colpo-
scopic images, which show regression of cervical lesions.
Conclusions
These results demonstrate the potential of Lopimune as a self-applied therapy for HPV
infection and related cervical lesions. Since there were no serious adverse events or detect-
able post-treatment morbidity, this study indicates that further trials are clearly justified to
define optimal regimes and the overall benefit of this therapy.
Trial Registration
ISRCTN Registry 48776874
Introduction
Infection with high-risk types of HPV has now been established as the main aetiological agent
for invasive cervical cancer (ICC)[1,2,3] and globally there are>270,000 deaths from this dis-
ease per annum with over 85% of these occurring in low resource countries[4]. In Kenya, the
setting for our trial, cervical cancer accounts for 23% of all female malignancies [5].
The development of ICC can take 10–20 years and is preceded by HPV related pre-invasive
pathology which are characterised as either low-grade (CIN1) or high-grade cervical intrae-
pithelial neoplasia (CIN2/3)[1]. These lesions can be screen detected by cervical cytology test-
ing where they are diagnosed as either borderline atypical squamous cells of undetermined
significance (ASCUS), low-grade squamous intraepithelial lesions (LSIL) or high-grade squa-
mous intraepithelial lesions (HSIL)[6].
The reduction in ICC related mortality in the developed world has been largely dependent
on organised cytology screening and similar trends in cervical cancer mortality have been
achieved by organised single screen and treatment in low resource settings [7]. However, in the
majority of these areas of the world, lack of resources and health education means that most
pre-invasive cervical disease remains undiagnosed and untreated. Thus, where funds are lim-
ited, low-cost screening and treatment options are clearly a high priority.
Current treatment options in clinical practice are either by ablative (destructive) or exci-
sional modalities which have similar success rates but have different morbidities [8]. In the
developed nations, Large Loop Excision of the Transformation Zone (LLETZ) or Loop Electro-
surgical Excision Procedure (LEEP) [9] is used in the majority of colposcopy clinics. Although
highly effective, this procedure is associated with a risk of primary/secondary haemorrhage,
prolonged vaginal discharge, infection and a risk of preterm delivery in subsequent pregnan-
cies, which can be problematic in low resource countries. Ablative cold coagulation and cryo-
therapy are often advocated for use in these settings although some studies have suggested that
these treatments have a higher failure rate when compared to other modalities [8,10].
There are a variety of locally-applied, non-surgical approaches which have been evaluated
for the treatment of cervical dysplasia (Reviewed by Stern et al [11] and Bernard [12]).
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However, although some of these alternative treatments show promise, their outcomes are gen-
erally inferior to the reported 80–95% success rates obtained with ablative/excisional modalities
when these are carried out in quality assured colposcopy units.
We originally speculated that HIV protease inhibitors (PIs) may have activity against HPV
related cervical disease and identified lopinavir as the most effective [13] although this was at
ten times the concentration achieved by oral dosing for HIV therapy [14]. Indeed, recent work
has shown that oral lopinavir, as used for normal HIV therapy, has little effect on HPV status
in HIV positive women [15]. Subsequent in vitro studies defined at least part of the mode-of-
action of lopinavir against HPV [16] and many HIV PI’s are now well known to have more
general anticancer properties [17,18,19]. Most notably, it has been suggested that ritonavir
(usually co-administred with lopinavir as Lopimune or Kaletra) may have anti-invasive and
anti-proliferative activity against cells derived from pre-invasive CINs but little activity against
cells derived from more advanced ICC [20].
Based on our pre-clinical studies it was concluded that direct application of lopinavir to the
cervix as a vaginal pessary or gel, might achieve the concentration required for activity against
HPV related cervical dysplasia. Since we already had research collaborations in place with clini-
cians at Kenyatta National Hospital/University of Nairobi in Kenya, we built on these to con-
duct a trial of self-applied lopinavir (in the form of Lopimune) in this setting with the aim of
developing an effective, inexpensive, non-surgical, self-applied treatment with minimal side
effects. We now report the results of a small, single-arm study to evaluate the safety, acceptabil-
ity and ability of Lopimune to induce clearance of HPV infection, and related dysplasia, in a
group of 23 women diagnosed with HSIL.
Methods
Patients and Study Centres
This was a collaborative proof-of-concept clinical trial between the University of Manchester
and the University of Nairobi/Kenyatta National Hospital (KNH), Kenya. Clinical and
basic diagnostic tests were done at KNH while scientific aspects of the study that required spe-
cialized equipment were carried out at the Viral Oncology Laboratory, St Marys Hospital in
Manchester, UK. KNH and the University of Nairobi Ethics and Research Committee (KNH/
UoN-ERC) approved the trial on the 25/11/2011, an extension was granted on the 07/01/2013
and the trial was conducted between 01/03/2013 and 01/11/2013. Patients were recruited from
women attending the Family Planning and Gynaecology Outpatient clinic at KNH for routine
follow up. Registration was carried out retrospectively (ISRCTN48776874) since the original
intention was to recruit a small number of patients to investigate acceptability of treatment.
Enrolment and Procedures
The study protocol is illustrated in Fig 1. At the screening stage, potential participants were
given the patient information sheet counselled appropriately and those willing to participate
gave informed signed consent. Thereafter, a structured questionnaire was used to take both the
socio-demographic, sexual histories and clinical characteristics (S2 Text), Blood was drawn for
a HIV test using DetermineTM (Abbott, USA) and if positive was confirmed by UnigoldTM
(Trinity Biotech, Ireland) as per Kenya HIV testing algorithm. All patients were then given a
speculum examination during which two cervical cyto-brush samples were taken. The first of
these was used for LBC ThinPrep1 and HPV testing and samples were immediately sent to
Manchester. The second was used for a conventional smear test as per standard Pap smear
screening procedures, which was examined and reported in Nairobi by the Kenyan study
pathologist. Patients were then reviewed after one month at which time those that were HIV
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negative and HPV positive with abnormal cervical cytology, were enrolled into the Lopimune
trial. It was decided this should be pragmatic in nature and biopsies were not taken at this
point since it is well known this can affect treatment outcomes [21]. Furthermore it was also
deemed important to avoid biopsy related bleeding or discharge since this would deter women
from attendng for follow-up assessments. Consequently two independent cytology slides (Con-
ventional reported by MPO and LBC reported by MD) were used to assess pre-treatment dis-
ease. HPV testing in combination with cytology and histology was used at the end of the study
to determine post-treatment outcomes.
At enrolment a pelvic examination was carried out which included baseline colposcopy.
Cervical morphology was initially visualised with acetic acid (VIA) followed by Lugol’s Iodine
(VILI) using x5 magnification (Video Colposcope, Welch Allyn. NY. USA). This was carried
out according to standard clinical practices and images recorded [22]. Blood was drawn for a
full blood count, urea, creatinine, electrolytes and liver function tests. Each patient was then
issued with a supply of Lopimune soft gel capsules (133 mg lopinavir/33 mg ritonavir, CIPLA,
India) for vaginal insertion of one capsule once or twice daily for a maximum of 2 weeks with
Fig 1. Patient screening, testing andmanagement flow chart used for the study.
doi:10.1371/journal.pone.0147917.g001
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the intention of block radomising the dose. Two additional visits per week were scheduled for
the two-week duration of Lopimune therapy during which a structured questionnaire was filled
out and a physical examination performed, both of which were conducted by either the Nairobi
PI (IOM) or study doctor (Dr Masinde, Resident in Gynaecology, University of Nairobi) in
order to assess occurrence of adverse drug reactions and drug compliance (S3 Text and S4
Text). Enrolled patients also had serial visits scheduled at 1, 2, 4, 8, 12 and 16 weeks. Follow up
LBC ThinPrep1 samples were taken at 4 and 12 weeks and sent to Manchester for cytology
and HPV testing. In addition, colposcopy with VILI was carried out at 4 and 12 weeks and
final punch biopsies were taken at the latter time point. Blood was also drawn at these visits for
baseline clinical tests described previously. The 8-week visit was to assess any potential drug
reactions and to remind women that a punch biopsy would be taken from any abnormal areas
detected by VIA or VILI on the cervix at the 12-week visit. Biopsies were stored in 10% buff-
ered formalin and were sent to Manchester. Those patients diagnosed with post-treatment,
HPV positive high-grade disease were referred for Loop electrosurgical excision procedure
(LEEP). These were reviewed again at 5 months and advised to continue routine Pap smear
screening at 6 months thereafter.
Cervista1 HR-HPV Test
All ThinPrep1 LBC samples sent to Manchester were analysed by staff trained and certified
by Hologic (Hologic, Bedford, MA). HPV testing of LBC samples was carried out using the
FDA-approved Cervista HPV HR test [23] in conjunction with the Cervista MTA (Hologic)
automated platform according to the manufacturer’s instructions. Prior to and after analysis,
all LBC samples were stored at +4°C in a monitored refrigerator.
HPV Genotyping
Ultrapure DNA isolated from each ThinPrep1 LBC sample which was used for the Cervista1
test, was then further analysed by PCR to test for which HPV genotypes were present in each
respective Cervista1mastermix positive sample. A novel hot-start, touch-down multiplex
method was used which simultaneously detects the L1, E6 and E7 ORFs of HPV type 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70 as previously described [24]. Each assay was
repeated a minimum of three times.
LBC ThinPrep1 Cervical Cytology
LBC slide preparation was carried out using the ThinPrep-2000 system (Hologic) automated
slide preparation unit, according to the manufactures directions and Pap stained (Hologic) at
the Regional Cytology Laboratories (Clinical Sciences Building, Manchester Royal Infirmary,
UK). Reporting of the LBC samples was done using a Dual Review Imaging System (Hologic).
Cervical Pathology
Final punch biopsy samples of the cervical transformation zone and VILI positive lesions were
transported to Manchester, wax embedded and 3–4μm sections cut at 3 levels according to
standard pathology laboratory practices. The sections were then stained with haematoxylin
and eosin and reported separately by two pathologists Independent review of cases where there
was disagreement was carried out by a third pathologist (Dr Bianca Da Gama Rose).
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Analysis of Lopinavir Concentration in Plasma
Lopinavir was extracted from plasma using a method based on that of Djerada et al [25].
MSMS analysis was carried out by use of an Agilent 6520 QTOF: 150-1000m/z targeted MSMS
629.37 between 2.5–5.5 min (50–800 m/z). Standard amounts of ultrapure research grade
lopinavir (Santa Cruz Biotechnology, Inc. Heidelberg, GMBH) comprising 1000, 500, 100, 50,
25, 12.5 and 6.25ng were added to control plasma and extracted as above. All test plasma
extractions and assays were performed in triplicate and were assayed with lopinavir control
standards.
Statistical Methods
Agreements between the conventional and ThinPrep cytology and the two study histopatholo-
gists were analysed by the McNemar test using R program version 3.1.2. All 95% confidence
intervals were computed using the R binom package and a p value< 0.05 was considered sta-
tistically significant.
Results
All baseline bloods and health checks were normal for the study participants.
Primary HPV and Cytology Screening
Fig 1 shows the management scheme for the 821 women screened of which 16 were HIV posi-
tive. Out of the remaining 805 HIV negative women, 164 (20.4%, 95%CI: 17.6–23.3%) were
Cervista1 positive for high-risk HPV. Out of these, cytology showed that 99 (60.3%, 95%CI:
52.5–67.9) were normal, 28 (17.1%, 95%CI: 11.7–23.7) had HSIL, 11 (6.7%, 95%CI: 3.4) had
LSIL and 21 (12.8%, 95%CI: 8.1–18.9%) had ASCUS. Five (3.0%, 95%CI: 1.0–7.0%) were diag-
nosed with ICC and were sent for immediate biopsy and subsequent treatment (hysterectomy).
Out of the 28 women identified with HSIL, 5 opted for alternative treatment with 23 eventually
being enrolled on the trial.
Lopimune Treatment of Women Diagnosed with HSIL
Table 1 shows the baseline characteristics of the 23 women diagnosed with HSIL who had an
average mean age of 34.2 yrs prior to being recruited into the trial. Predictably, a combined rel-
atively high incidence of HPV types 16 and 18 was detected which amounted to 10/23 (43.5%,
95%CI: 23.2–65.5%) of cases. With 5 infections, type 52 was the next most common followed
by 4 infections each for types 35, 58 and 33. On one occasion Cervista1 detected a positive for
more than one master mix whereas PCR only detected one HPV genotype present which could
be due to differences in sensitivity between these methods. A good concordance between HSIL
diagnosed by LBC in Manchester and conventional smear testing carried out in Kenya was
observed with only 3/23 disparities. McNemar test demonstrated a p-value of 0.32 which con-
firmed there was no significant difference between these two modalities.
The original intention was to block randomise Lopimune treatment starting at the higher
dose. However, due to the nature of recruitment being few patients spaced by long time inter-
vals, it was noted that the twice-daily dose produced excellent cervical lesion clearance with no
significant adverse effects. This prompted the decision to adopt an adaptive design and aban-
don the planned lower dose arm since no patient had been put on the lower dose at that time.
The study, therefore, became a single-arm non-randomized trial.
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Adverse Reactions, Tolerability and Adherence to Treatment
In the 4 weeks post start-of-treatment there were no serious adverse reactions or drug events
such as death, life-threatening events, hospitalization or disability observed. Additionally, none
of the study subjects reported, vaginal dryness, bleeding/spotting, painful intercourse, palpita-
tions, unusual weakness, vomiting, decreased appetite, diarrhoea, pale stools, itchy skin, skin
rashes, increased thirst, increased frequency of urination, visual disturbance, chest pains, or
jaundice. However, there were some minor side-effects (Table 2) but only nausea achieved sta-
tistical significance (p = 0.037). The commonest complaint by study subjects was headache (3/
13%) followed by vaginal irritation (2/8.7%); nausea (2/8.7%); feeling faint/dizziness (2/8.7%),
abnormal vaginal discharge (2/8.7%) and abdominal pains (1/4.3%). In total, 5/21.7% of study
subjects experienced some form of minor complaint within the 1st month of taking Lopimune
as described.
Table 1. Participant characteristics at study baseline.
Characteristics Results at baseline n(% of
23)
Age: Mean (SD) 35.4 years (±10.4)
Median (interquartile range) 37 years (27–41)
Birth Control Method
• Condom 2 (8.6)
• Tubal ligation 1 (4.3)
• Depoprovera or Implant 5 (21.7)
• Intrauterine device 5 (21.7)
• None 9 (39.1)
• Post-menopausal 1 (4.3)
Parity
• Nulliparous 3 (13.0)
• 1–4 live births 17 (73.9)
• >4 live births 3 (13.0)
HPV results
• Cervista Mix 1 only (M1) (HPV 51, 56, 66, or 70) positive 1 (4.3)
• Cervista Mix 2 only (M2) (HPV 18, 39, 45, 59, 68) positive 4 (17.4)
• Cervista Mix 3 only (M3) (HPV 16, 31, 33, 35, 52, 58) positive 14 (60.0)
• Cervista Mix 1 + Mix 3 positive 2 (8.6)
• Cervista Mix 2 + Mix 3 positive 2 (8.6)
High-Risk HPV typing by PCR
• HPV16 only 2 (8.6)
• HPV16 + Non-HPV16 types 5 (21.7)
• Non-HPV16 types only (HPV18/31/33/35/39/45/51/52/56/58/59/68/
70)
16 (69.6)
Cytology Results: Liquid Based Cytology
• Moderate dyskaryosis: HSIL 10 (43.5)
• Severe dyskaryosis: HSIL 13 (56.5)
Cytology Results: Conventional Cytology
• LSIL 1 (4.3)
• ASC-H with or without AGC 2 (8.6)
• HSIL 20 (87.0)
ASC-H abnormal squamous cells–cannot exclude HSIL; AGC abnormal glandular cells.
doi:10.1371/journal.pone.0147917.t001
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Information on drug adherence was self-reporting and 10 (43.5%) of patients completed
their treatment on schedule without skipping a dose. Out of the remaining 13, 7 (53.8%) missed
once, 2 (15.4%) missed twice, 1 (7.6%) missed three times, 2 (15.4%) missed for times and one
subject missed 5 consecutive doses. The commonest reason for skipping doses was interruption
by menstrual flow (6/46.2%), forgot (5/38.5%) and the inconvenience of carrying refrigerated
Lopimune whilst away from home (2/15.4%). Significantly, none of the subjects skipped due to
side-effects, problems inserting pessaries or because their partner wanted intercourse. Indeed,
despite being advised to abstain during the treatment period, 5 (21.7%) of patients still reported
as having had intercourse at least once. Neither omitted doses nor engaging in sexual inter-
course had any statistically significant effect on the observed treatment outcomes.
Treatment outcome of Lopimune on HPV and related dysplasia
The results of repeat ThinPrep1 LBC and Cervista1HPV tests carried out at 4 and 12 weeks
post-start of treatment are summarised in Table 3 and Fig 2A, 2B and 2C. HPV genotypes pres-
ent are shown above each bar of which the height indicates the level of HPV detected in each
patient. This demonstrates that a post-treatment drop in the levels of HPV infection was
observed in 19/23 (82.6%, 95%CI: 61.2–95.0%) with the virus not detected in 12/23 (52.2%,
95%CI: 30.6–73.2) of women 12 weeks after the start of treatment.
A total of 22 patients were reported at 4 and 12 weeks since E19 had inadequate cellularity
for HPV testing and cytology at 4 weeks whereas E15 was adequate for HPV testing but not
cytology at 12 weeks. After 4 weeks (Fig 2B) 14/22 (63.6%, 95%CI: 40.6–82.8%) of patients had
returned to normal cytology and 3/22 (13.6%, 95%CI: 2.91–34.9%) now had lower grade dis-
ease demonstrating a positive response in 769% of women. After 12 weeks (Fig 2C) 14/22
(63.6%, 95%CI: 40.6–82.8) of women still had normal cytology with 4/22 (18.2%, 95%CI: 5.2–
40.3%) now presenting with lower grade dysplasia providing an overall positive response in
81.8% of women.
Comparison of histopathology results with cytology at 12 weeks showed that 13/22 (59.1%,
95%CI: 36.4–79.3%) had no detectable dysplasia and 4/22 (18.2%, 95%CI: 9.9–65.1%) had
CIN1, which equates to a 77.3% positive response to treatment. Only 4/22 (18.2%, 95%CI: 9.9–
65.1%) had CIN2 or CIN3 and 1/22 (4.5%, 95%CI: 0.1–22.9%) had hCGIN. A total of 22
patients were reported for pathology since the biopsies obtained from E19 at 12 weeks were
inadequate and thus excluded from the analysis. McNemar test demonstrated a p-value of
0.025 which indicated that there was a statistically significant difference in reporting by the two
study pathologists which was resolved by referral to a third independent pathologist.
Table 2. Symptoms experienced by study subjects within onemonth of starting Lopimune treatment.
Week 1 Week 2 Week 4 Total p-value
Patient complaints: No. % No. % No. % No. %
Abnormal vaginal discharge 2 8.7 1 4.3 - - 2 8.7 0.134
Vaginal irritation 2 8.7 - - 1 4.3 2 8.7 0.617
Headaches 1 4.3 2 8.7 - - 3 13.0 0.617
Nausea 2 8.7 - - - - 2 8.7 0.037
Abdominal pains - - 1 4.3 - - 1 4.3 0.803
Total No. of patients affected 4 17.4 4 17.4 1 4.3 5 21.7
(Note:- Some patients had more than one symptom, n = 23)
doi:10.1371/journal.pone.0147917.t002
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Colposcopy with VILI
Fig 3 shows VILI colposcopic images of the cervix from 5 cases diagnosed with HSIL taken
before, 4 and 12 weeks after treatment with Lopimune capsules. Extensive yellow/orange stain-
ing characteristic of poorly glycogenated dysplastic epithelium, was clearly present in all the
pre-treatment images of the ectocervix and the cases shown were deliberately chosen to illus-
trate the types of response observed. The majority of patients showed a reduction in dysplastic
epithelium, as detected by VILI, which was associated with reduced severity of disease as indi-
cated by HPV, cytology and/or pathology status. For example patient E02 became HPV nega-
tive at 4 and 12 weeks and also clearly showed a marked regression of dysplastic epithelium
detected by VILI although a small focus of CIN2 was still present. Patient E03 remained HPV
positive at 4 and 12 weeks with normal cytology at 4 weeks and yet showed HSIL cytology with
CIN1 and hCGIN at 12 weeks. E06 remained HPV positive with HSIL cytology after 12 weeks
although pathology subsequently showed this to be CIN1. E14 and E12 both showed return to
normal cytology at 4 and 12 weeks with no CIN present at 12 weeks although E12 remained
HPV positive.
Analysis of Plasma Levels of Lopinavir
Extracted ion chromatograms of research grade lopinavir showed this to have a mass/charge
ratio of 629.37 m/z eluting at 5.1 min. Extraction of compound from control plasma was
Table 3. Changes in cytology and HPV results between baseline and 3-month visits following Lopi-
mune treatment.
Characteristics Change between baseline and
3-months exit visit n(% of 23)
Change in HPV results
• Any Cervista HPV-positive to Cervista HPV-negative 12 (52.2)
• Cervista Mix 1 only (M1) (HPV 51, 56, 66, or 70) positive
to Cervista HPV-negative
1 (4.3)
• Cervista Mix 2 only (M2) (HPV 18, 39, 45, 59, 68) positive
to Cervista HPV-negative
1 (4.3)
• Cervista Mix 3 only(M3) (HPV 16, 31, 33, 35, 52, 58)
positive to Cervista HPV-negative
9 (39.1)
• Cervista Mix 1 + Mix 3 1 (4.3)
• Cervista Mix 2 + Mix 3 0 (0.0)
Change in HPV16 and Non-HPV16 Types
• HPV16 only to HPV negative 1 (4.3)
• HPV16 + Non-HPV16 types 2 (8.6)
• Non-HPV16 high risk types (HPV18/31/33/35/39/45/51/
52/56/58/59/68) to HPV negative
9 (39.1)
Change in liquid based cytology*
• Any improvement in cytology 18 (81.8)
• HSIL to negative 14 (63.6)
 Moderate dyskaryosis: HSIL to negative 5 (22.7)
 Severe dyskaryosis: HSIL to negative 9 (40.9)
• HSIL to LSIL/ASCUS 4 (18.2)
 Moderate dyskaryosis: HSIL to LSIL/ASCUS 3 (13.6)
 Severe dyskaryosis: HSIL to LSIL/ASCUS 1 (4.5)
* Since one LBC sample was inadequate, percentages were calculated from n = 22.
doi:10.1371/journal.pone.0147917.t003
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shown to be>90% efficient when compared to the same amount of drug added directly to sol-
vent prior to analysis and could detect lopinavir to a level of ~6.00 ng/ml when added to
plasma. Out of 23 samples tested, the maximum level of drug detected in patient plasma, after
one week of vaginal delivery, was approximately 10 ng/ml although most samples were lower
than this.
Discussion
When used for oral HIV therapy, lopinavir is normally co-adminstered in a 4:1 ratio with rito-
navir (Lopimune- CIPLA; Kaletra- AbbVie). Due to cost and supply issues, reformulation of
lopinavir as a single agent was not possible so evaluation of the orally-administered Lopimune
gelatine capsule formulation was undertaken with the axiom this might serve as a vaginal pes-
sary for local delivery to the cervix. Clearly the local concentration of drug achieved by this
mode of delivery will be much higher than the 74–215 ng/ml previously reported in cervico-
vaginal fluid as a result of normal oral dosing for HIV therapy [14]. Analysis of plasma levels of
lopinavir one week after starting vaginal treatment, demonstrated that the drug was being
Fig 2. Cervista1 HPV test, cytology and PCR HPV genotype analysis.HPV titre is indicated by the height of the bar graph above the cut off with the Y
axis representing the fold over zero (FOZ) ratio of sample or control divided by the no target control signal. The cytology status is indicated by colour and
shading with the HPV type shown above the bar. (A) Represents the results before treatment with lopinavir; (B) Represents results after 4 and (C) 12 weeks
after treatment.
doi:10.1371/journal.pone.0147917.g002
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Fig 3. Colposcopy with VILI before, 4 weeks and 12 weeks after treatment for patients E02, E03, E06,
E14 and E12.Magnification x5 was used with the Cervista1 HPV status and cytology shown under each
picture and final pathology (CIN status) also shown under the 12 weeks post-treatment images.
doi:10.1371/journal.pone.0147917.g003
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absorbed systemically by this route of administration although levels of 10 ng/ml or less,
showed that the concentration achieved was much lower than the 2.8–6.6 μg/ml previously
reported for normal HIV therapy [14]. Nevertheless, these findings are consistent with the aim
of treating cervical dysplasia whilst limiting systemic exposure to the drug.
The primary outcome was to assess tolerability and any adverse events associated with local
application of this treatment to the cervix. Out of 23 women treated, no significant serious
adverse indications were reported. Compliance was good and Lopimune was well tolerated
with few side-effects and only nausea achieving statistical significance. Acceptability was also
good, given that none of the subjects omitted a dose because of side-effects or because their
partner wanted sexual intercourse. Moreover, 5 patients had intercourse during the treatment
period and yet this did not appear to affect treatment outcome which suggests this may not be
need to restricted. However, further study is clearly required to investigate this possibility.
A potential criticism of this study was the reliance on cytology for the pre-treatment and 4
week follow up diagnosis of underlying cervical dysplasia since it is well known that there is
considerable variation (30–80%) in the accuracy of cytology between different centres through-
out the world [26]. The Manchester-based cytology procedures, used in the current trial, were
identical to those reported in the ARTISTIC study [27], which achieved>76% prediction of
CIN2/3 from a diagnosis of HSIL.
Another potential criticism is the lack of a placebo control arm since CIN2/3 lesions can
spontaneously regress if left untreated although there is a paucity of data regarding natural
regression rates over a 3 month period with the majority of published work analysing this over
6 to 12 months or longer. However, a study, conducted by Alvarez et al, did report over 3
months and found that ~30% of CIN2/3 lesions regressed in this period [28] which was consid-
erably higher than the 5% regression rate predicted by these authors. Moreover, they speculated
that these higher than anticipated regression rates may have been due to biopsy related inflam-
matory changes [21] and yet, even allowing for similar spontaneous regression rates, this
would not account for those observed in the current study.
Comparison of histopathology with cytology at 12 weeks post-treatment was mostly consis-
tent although there were some differences. However, pathology still showed that ~60% of
women had no detectable neoplasia at 12 weeks and others had reduced severity of disease
(CIN1) indicating a combined positive response in ~77% of women. Most significantly these
rates of regression are generally higher than would be predicted for untreated cases of high-risk
HPV positive CIN2/3 [29].
Regarding the different HPV genotypes present, there was no significant correlation with
response to treatment for any of those identified nor was there any obvious correlation with
other socio-demographic factors such as age, type of contraception used, number of lifetime
sexual partners or parity. Notably, none of the women in this study smoked.
How does the current treatment with Lopimune compare to other non-surgical treatments
for cervical dysplasia? PDT has been extensively evaluated for this purpose with a large range
of response rates ranging from 0–100% for CIN and 534–80% eradication of HPV [30]. Disad-
vantages are that PDT is physician applied with each sequential treatment typically taking sev-
eral hours. Also systemic use of photosensitizers can cause problems with general skin
sensitization to light. Topical application with the cytotoxic anti CMV drug Cidofovir has been
used to treat CIN2/3 and showed ~60% clearance of CIN but did not eliminate HPV infection
as assessed by the hybrid capture 2 assay [31]. Direct application of the immune activator Imi-
quimod to the cervix has been shown to have some effect against CIN and HPV infections both
before and after LEEP although the treatment is continued for>8 weeks and the side effects
can be quite severe [32,33]. A recent study of topical application of the cytotoxic drug 5FU to
the cervix showed this to be>90% effective against CIN2 lesions in young women aged 18–29
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although this was physician applied and the treatment period lasted 16 weeks [34]. A review of
pharmacological approaches for the treatment of HPV related lesions was carried out by Ber-
nard in 2004 [12] with the conclusion that none were generally recommended due to side
effects and limited efficacy. Clearly, application of these modalities has improved in recent
years although there are still many issues surrounding their implementation into clinical
practice
The current study illustrates the potential of Lopimune to serve as an effective alternative to
surgery for the treatment of HPV related cervical dysplasia although it is clear that the dose
and regimen used in our study were sub-optimal and need further refinement. Evidence for
this was that some women showed a transient improvement in HPV and/or cytology at 4
weeks but then went on to develop HPV positive abnormal cytology/pathology at 12 weeks
(See Fig 2 E03, E13, E17). Advantages of this therapy are that; it can be self-applied,; it is rela-
tively cheap (~£10.00 per patient for the current treatment protocol as purchased from Kenyan
pharmacy in 2013); it is a non-cytotoxic FDA approved drug which does not target DNA and
it has very good safety profile with a current license for the long-term systemic treatment of
HIV infected pregnant women and children [35]. Furthermore, since HPV is DNA based and
is more stable then RNA based HIV, it is less likely to develop resistance to drugs such as Lopi-
mune which implies that, in principle, this treatment could be repeated many times.
In conclusion, this exploratory study illustrates the potential use of Lopimune as a self-
administered treatment for HSIL with associated clearance of high risk HPV infections. It is
very clear that more robust trials are needed to validate this new indication which would be
particularly useful in low resource settings.
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